Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
66.90    -1.10 (-1.62%)
Bid:
66.80
Ask:
67.00
Spread: 0.20 (0.299%)
Market Cap: £591.01m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Share buyback programme

18 Dec 2023 07:00

RNS Number : 0631X
IP Group PLC
18 December 2023
 

FOR RELEASE ON

18 December 2023

 

 

IP Group plc - Share buyback programme

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, announces that it has today launched a share buyback.

In light of the prevailing discount between the Company's share price and its NAV per share, the Board has determined that now is an appropriate time, consistent with its commitment to shareholder returns, to initiate a share buyback of up to £20 million (the "Buyback Programme").

 

The Directors believe the current share price discount to NAV significantly undervalues IP Group's portfolio. They have therefore determined to allocate a proportion of cash realisations to shareholder returns through the Buyback Programme. As at 30 November 2023, IP Group had achieved cash realisations of £38 million and had gross cash of £235 million.

 

The Board remains committed to making regular cash returns to shareholders from realisations. In future these regular cash returns will normally be made in the form of share buybacks when the share price discount to NAV exceeds 20%. Regular dividend payments will be suspended under such conditions, including consideration of any final dividend for 2023.

 

Details of the Buyback Programme

 

IP Group has entered into a non-discretionary arrangement with Deutsche Numis to manage the Buyback Programme on its behalf under which the Group will repurchase ordinary shares of 2 pence each in IP Group ("Ordinary Shares") up to an aggregate consideration of £20.0 million. This will be done within certain parameters, including to only buy back Ordinary Shares at a greater than 20% discount to the most recently announced NAV per share. The Buyback Programme will run from the date of this announcement until the end of 2024 unless completed or terminated earlier. Deutsche Numis will make its trading decisions in relation to the Ordinary Shares independently of the Group. 

Purchases of Ordinary Shares pursuant to the Buyback Programme will take place in open market transactions and may be made from time-to-time depending on market conditions, the Group's share price, trading volumes in the Group's Ordinary Shares and other factors. The maximum price paid per Ordinary Share (exclusive of expenses) will be no more than the higher of: (i) 5 per cent above the average of the middle market quotations taken from the London Stock Exchange Daily Official List for the five business days preceding any Ordinary Shares being purchased; and (ii) the higher of the price of the last independent trade and the highest independent bid for Ordinary Shares on the trading venue where the purchase is carried out. The minimum price shall be no less than (exclusive of expenses) a price of 2 pence per Ordinary Share, being the nominal value of an Ordinary Share. Under the Buyback Programme, any Ordinary Shares purchased will be held in treasury.

The Buyback Programme is in accordance with IP Group's general authority to purchase a maximum of 103,677,065 Ordinary Shares, granted by its shareholders at the Annual General Meeting held on 15 June 2023. The Buyback Programme will also be effected within the parameters of the Market Abuse Regulation 596/2014/EU and the Commission Delegated Regulation 2016/1052/EU (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), including where relevant pursuant to the Market Abuse (Amendment)(EU Exit) Regulations 2019), and in accordance with Chapter 12 of the Financial Conduct Authority's Listing Rules. IP Group confirms that it is not in a closed period and currently has no other unpublished price sensitive information.

IP Group will make further regulatory announcements to shareholders in respect of purchases of Ordinary Shares by the Group as they occur.

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7967 312125

Portland

Vic Wallin

Alex Donaldson

+44 (0) 7973 823119

+44 (0) 7516 729702

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. Athe most active UK based, early stage science investorwe develop and support some of the world's most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutionsOur specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCVDLBFXLLLFBE
Date   Source Headline
6th Jul 20187:00 amRNSNotification of Major Interest in Shares
4th Jul 20182:40 pmRNSCeres Power announces £20m fundraising
2nd Jul 20187:00 amRNSHolding(s) in Company
27th Jun 20187:30 amRNSCarisma announces $53m Series A funding round
27th Jun 20187:00 amRNSNotification of Major Interest in Shares
22nd Jun 201810:00 amRNSAppointment of Joint Broker
18th Jun 20181:37 pmRNSResult of AGM
7th Jun 20186:00 pmRNSHolding(s) in Company
6th Jun 20189:26 amRNSMicrobiotica signs collaboration worth up to $534m
16th May 201810:49 amRNSPortfolio co Ceres partners with Weichai Power
16th May 20187:00 amRNSNotice of AGM; Annual Report
11th May 20187:00 amRNSDirector/PDMR Shareholding
10th May 20186:18 pmRNSDirector/PDMR Shareholding
9th May 20185:31 pmRNSDirector share purchase
4th May 20187:00 amRNSBoard changes
30th Apr 20187:00 amRNSTotal Voting Rights
16th Apr 20185:45 pmRNSDirector/PDMR Shareholding
12th Apr 20189:19 amRNSEnterprise Therapeutics raises £29m
5th Apr 20181:12 pmRNSIP Group plc - Issue of Equity
4th Apr 201811:46 amRNSIP Group plc - Director/PDMR share purchase
29th Mar 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSOxford Nanopore announces £100m fundraising
17th Jan 201811:53 amRNSHolding(s) in Company
10th Jan 20189:12 amRNSHolding(s) in Company
2nd Jan 20187:00 amRNSTotal Voting Rights
18th Dec 201710:15 amRNSAutifony signs Eur627.5m agreement with BI
15th Dec 201712:50 pmRNSDiurnal receives positive CHMP opinion for Alkindi
14th Dec 20174:48 pmRNSDirectorate Change
13th Dec 20172:27 pmRNSIssue of Equity
8th Dec 20177:05 amRNSMirriad raises £26.2m; proposed admission to AIM
6th Dec 20172:32 pmRNSIssue of Equity
30th Nov 201712:40 pmRNSTotal Voting Rights
27th Nov 20176:27 pmRNSIssue of Equity
22nd Nov 20175:50 pmRNSHolding(s) in Company
22nd Nov 20173:23 pmRNSIssue of Equity
15th Nov 201712:47 pmRNSIssue of Equity
14th Nov 201712:29 pmRNSHolding(s) in Company
13th Nov 20177:00 amRNSNotice of cancellation of admission to AIM
9th Nov 201711:11 amRNSIssue of Equity
8th Nov 20175:11 pmRNSHolding(s) in Company
6th Nov 20173:50 pmRNSIssue of Equity
6th Nov 20177:00 amRNSHolding(s) in Company
2nd Nov 20177:00 amRNSHolding(s) in Company
31st Oct 20175:35 pmRNSHolding(s) in Company
31st Oct 20175:20 pmRNSTotal Voting Rights
26th Oct 20173:50 pmRNSIssue of Equity
19th Oct 20173:20 pmRNSForm 8.3 - IP Group PLC
19th Oct 201710:38 amRNSForm 8.5 (EPT/RI) - IP Group Plc
18th Oct 20175:02 pmRNSForm 8.5 (EPT/RI) - IP Group Plc Amendment
18th Oct 20173:20 pmRNSForm 8.3 - IP Group PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.